Compositions and methods for treating chronic inflammation and inflammatory diseases

1. A pharmaceutical composition comprising:

a) a therapeutic compound, wherein the therapeutic compound has an anti-inflammatory activity;

b) about 1% (v/v) to about 10% (v/v) of a pharmaceutically-acceptable solvent; and

c) at least 85% (v/v) of a pharmaceutically-acceptable lipid-adjuvant,

wherein the pharmaceutically-acceptable lipid-adjuvant is a fatty acid having at least 12 carbons, a glycerolipid, a sphingolipid, a sterol lipid, a prenol lipid, a saccharolipid, or a polyketide,

wherein the pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower.

2. The pharmaceutical composition according to claim 1 , wherein the anti-inflammatory activity reduces the level of an inflammation inducing molecule.

3. The pharmaceutical composition according to claim 1 , wherein the anti-inflammatory activity reduces the level of an inflammation inducing prostaglandin.

4. The pharmaceutical composition according to claim 1 , wherein the anti-inflammatory activity stimulates a PPAR signaling pathway.

5. The pharmaceutical composition according to claim 1 , wherein the anti-inflammatory activity induces apoptosis of Macrophage M1 cells, promotes differentiation of Macrophage M2 cells, or both.

6. The pharmaceutical composition according to claim 1 , wherein the anti-inflammatory activity reducing the levels of Interferon-gamma (IFNγ), Tumor necrosis factor-alpha (TNF-α), Interleukin-12 (IL-12), or a combination thereof released from Th1 cells, increases the levels of IL-10 released from a Th2 cell, or both.

7. The pharmaceutical composition according to claim 1 , wherein the therapeutic compound comprises a non-steroidal anti-inflammatory drug (NSAID).

8. The pharmaceutical composition according to claim 7 , wherein the NSAID comprises a salicylate derivative NSAID, a p-amino phenol derivative NSAID, a propionic acid derivative NSAID, an acetic acid derivative NSAID, an enolic acid derivative NSAID, a fenamic acid derivative NSAID, a non-selective cyclo-oxygenase inhibitor, a selective cyclooxygenase 1 inhibitor, a selective cyclooxygenase 2 inhibitor or a combination thereof.

9. The pharmaceutical composition according to claim 1 , wherein the therapeutic compound comprises a PPARγ agonist.

10. The pharmaceutical composition according to claim 9 , wherein the PPARγ agonist comprises Monascin, Irbesartan, Telmisartan, mycophenolic acid, Resveratrol, Delta(9)-tetrahydrocannabinol, a cannabidiol, Curcumin, Cilostazol, Benzbromarone, 6-shogaol, glycyrrhetinic acid, a thiazolidinedione, a NSAID, a fibrate, or a combination thereof.

11. The pharmaceutical composition according to claim 10 , wherein the fibrate comprises Bezafibrate, Ciprofibrate, Clofibrate, Gemfibrozil, Fenofibrate, or a combination thereof.

12. The pharmaceutical composition according to claim 1 , wherein the therapeutic compound comprises an ester of the therapeutic compound.

13. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically-acceptable solvent comprises a pharmaceutically-acceptable polar aprotic solvent, a pharmaceutically-acceptable polar protic solvent, a pharmaceutically-acceptable non-polar solvent, or a combination thereof.

14. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically-acceptable solvent comprises a pharmaceutically-acceptable alcohol.

15. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically-acceptable solvent comprises a pharmaceutically-acceptable ester of pharmaceutically-acceptable alcohol and an acid.

16. The pharmaceutical composition according to claim 1 , wherein the adjuvant is at least 90% (v/v).

17. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically-acceptable adjuvant comprises a pharmaceutically-acceptable lipid.

18. The pharmaceutical composition according to claim 17 , wherein the pharmaceutically-acceptable lipid comprises a saturated fatty acid, an unsaturated fatty acid, or a combination thereof.

19. The pharmaceutical composition according to claim 17 , wherein the pharmaceutically-acceptable lipid comprises a pharmaceutically-acceptable oil.

20. The pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition further comprises a pharmaceutically-acceptable stabilizing agent, wherein the pharmaceutically-acceptable stabilizing agent is not an emulsifying agent.

21. The pharmaceutical composition according to claim 20 , wherein the pharmaceutically-acceptable stabilizing agent comprises water, a sacrificial acid comprising a fatty acid component and acetic acid, ethyl acetate, a sodium acetate/acetic acid, a monoglyceride, an acetylated monoglyceride, a diglyceride, an acetylated diglyceride, a fatty acid, a fatty acid salt, or a combination thereof.

22. A method of treating an individual with a chronic inflammation, the method comprising the step of: administering to the individual in need thereof a pharmaceutical composition according to claim 1 , wherein administration results in a reduction in a symptom associated with the chronic inflammation, thereby treating the individual.

23. The method according to claim 22 , wherein the chronic inflammation is associated with acne, acid reflux/heartburn, age related macular degeneration, allergy, allergic rhinitis, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, appendicitis, arteritis, arthritis, asthma, atherosclerosis, autoimmune disorders, balanitis, blepharitis, bronchiolitis, bronchitis, a bullous pemphigoid, burn, bursitis, cancer, cardiac arrest, carditis, celiac disease, cellulitis, cervicitis, cholangitis, cholecystitis, chorioamnionitis, chronic obstructive pulmonary disease, cirrhosis, colitis, congestive heart failure, conjunctivitis, cyclophosphamide-induced cystitis, cystic fibrosis, cystitis, common cold, dacryoadenitis, dementia, dermatitis, dermatomyositis, diabetes, diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, diabetic ulcer, digestive system disease, eczema, emphysema, encephalitis, endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis, fibromyalgia, fibrosis, fibrositis, gastritis, gastroenteritis, gingivitis, glomerulonephritis, glossitis, heart disease, heart valve dysfunction, hepatitis, hidradenitis suppurativa, Huntington's disease, hyperlipidemic pancreatitis, hypertension, ileitis, infection, inflammatory bowel disease, inflammatory cardiomegaly, inflammatory neuropathy, insulin resistance, interstitial cystitis, interstitial nephritis, iritis, ischemia, ischemic heart disease, keratitis, keratoconjunctivitis, laryngitis, lupus nephritis, mastitis, mastoiditis, meningitis, metabolic syndrome, a migraine, multiple sclerosis, myelitis, myocarditis, myositis, nephritis, non-alcoholic steatohepatitis, obesity, omphalitis, oophoritis, orchitis, osteochondritis, osteopenia, osteomyelitis, osteoporosis, osteitis, otitis, pancreatitis, Parkinson's disease, parotitis, pelvic inflammatory disease, pemphigus vularis, pericarditis, peritonitis, pharyngitis, phlebitis, pleuritis, pneumonitis, polycystic nephritis, proctitis, prostatitis, psoriasis, pulpitis, pyelonephritis, pylephlebitis, renal failure, reperfusion injury, retinitis, rheumatic fever, rhinitis, salpingitis, sarcoidosis, sialadenitis, sinusitis, spastic colon, stenosis, stomatitis, stroke, surgical complication, synovitis, tendonitis, tendinosis, tenosynovitis, thrombophlebitis, tonsillitis, trauma, traumatic brain injury, transplant rejection, trigonitis, tuberculosis, tumor, urethritis, ursitis, uveitis, vaginitis, vasculitis, or vulvitis.

24. The method according to claim 22 , wherein the chronic inflammation is a tissue inflammation or a systemic inflammation.

25. The method according to claim 22 , wherein the chronic inflammation is an auto-immune disease or a non-autoimmune disease.

26. The method according to claim 22 , wherein the chronic inflammation is associated with an arthritis, a myopathy, a vasculitis, a skin disorder, a gastrointestinal disorder, a cardiovascular disease, a cancer, a pharmacologically-induced inflammation, an infection, a tissue or organ injury, a transplant rejection, a graft-versus-host disease, a Th1-mediated inflammatory disease, a chronic neurogenic inflammation.

27. The method according to claim 22 , wherein upon administration to the individual, the pharmaceutical composition comprising the therapeutic compound results in a bio-distribution of the therapeutic compound different than a bio-distribution of the therapeutic compound included in the same pharmaceutical composition, except without the pharmaceutically-acceptable adjuvant.

28. The method according to claim 22 , wherein upon administration to the individual, the pharmaceutical composition reduces gastric or intestinal irritation by at least 5% when compared to the pharmaceutical composition, except without the pharmaceutically-acceptable adjuvant.